In elderly patients with advanced melanoma and idiopathic pulmonary fibrosis receiving active antifibrotic therapy, would neoadjuvant or adjuvant immune checkpoint inhibition be preferred?  

I'd be very careful with the use of immunotherapy in an elderly patient with any sort of autoimmune disease, especially when receiving disease-modifying therapy. Having said that, there is no such contraindication to giving immunotherapy in such patients. Neoadjuvant setting: It is always prefer...

additional information is needed to weigh risk and benefit as well as life expectancy becore making a decision